Free shipping on all orders over $ 500

TRAM-34

Cat. No. M3192
TRAM-34 Structure
Synonym:

Triarylmethane-34

Size Price Availability
25mg USD 160 Out of stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

TRAM-34 is a selective and potent inhibitor of the intermediate-conductance Ca2+-activated K+ channel (IKCa1, KCa3.1) with Kd of 20 nM. Unlike clotrimazole, TRAM-34 dose not inhibit mammalian cytochrome P450 enzyme (CYP3A4). TRAM-34 displays >200-fold selectivity for IKCa1 over Kv, BKCa, SKCa, Na, CRAC, and chloride channels. TRAM-34 does not exhibit toxicity against a variety of cell lines in vitro or cause obvious deleterious changes in a limited short-term acute toxicity study in rodents. TRAM-34 significantly inhibits the reactivation process of human lymphocytes by mitogenic stimuli, and when in combination with cyclosporin A suppresses T-cell mitogenesis more potently than either compound alone. TRAM-34 significantly inhibits EGF-induced IKCa1 up-regulation, and EGF-stimulated proliferation of A7r5 cells. TRAM-34 treatment at 120 mg/kg/day significantly reduces intimal hyperplasia in rat model of balloon catheter injury (BCI). TRAM-34 inhibits human endometrial cancer (EC) cell proliferation, arrests its cell cycle at G0/G1 phase, and suppresses the development of EC tumors in nude mice. By specifically targeting IKCa1, TRAM-34 treatment inhibits the prostate cancer (PCa) cell proliferation in a dose-dependent manner, involving growth arrest and an accumulation of p21Cip1.

Protocol
Cell Experiment
Cell lines Human T lymphocytes, Jurkat E6-1, MEL, C2F3, CHO, COS-7, L929, NGP, NLF, and RBL-2H3
Preparation method Exposing cells to TRAM-34 for 48 hours. 48 hours later , cells are harvested by suction (suspension cells) or by trypsinization (adherent cell lines), centrifuged, resuspended in 0.5 mL PBS containing 1 μg/mL propidium iodide (PI), and measured red fluorescence on a FACScan flow cytometer. The percentage of dead cells is determined by their PI uptake, 104 cells of every sample being analyzed.
Concentrations Dissolved in DMSO, final concentration ~10 μM
Incubation time 48 hours
Animal Experiment
Animal models Sprague-Dawley rats subjected to BCI of the left CA by use of a 2F Fogarty embolectomy catheter
Formulation Formulated in peanut oil
Dosages 120 mg/kg/day
Administration Subcutaneous injection
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 344.84
Formula C22H17ClN2
CAS Number 289905-88-0
Purity 99.75%
Solubility DMSO
Storage at -20°C
Related Potassium Channel Products
2,2,2-Trichloroethanol

2,2,2-Trichloroethanol is an agonist for the nonclassical K2P channels TREK-1 (KCNK2) and TRAAK (KCNK4).

Nigericin

Nigericin is an antibiotic derived from Streptomyces hygroscopicus, it acts as an H+, K+, Pb2+ ionophore.

ML213

ML213 (CID-3111211) is a selective KV7.2 (KCNQ2) and KV7.4 (KCNQ4) channel opener, with EC50 values of 230 and 510 nM for KV7.2 and KV7.4, respectively.

CLP290

CLP290 is a novel, orally available KCC2 modulator, highly selective for KCC2 over related Cl- transporters.

BMS-191011

BMS-191011 is a potent BKCa channel opener (large-conductance Ca2+-activated potassium channel, KCa1.1).

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: TRAM-34, Triarylmethane-34 supplier, Potassium Channel, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.